Is Abbott Laboratories (ABT) Still Undervalued On Volt’s First US And Canada Procedures?

Abbott Laboratories (ABT) has just seen its Volt Pulsed Field Ablation System move from approval to real world use, with first procedures reported in both Canada and the United States. For context, Abbott Laboratories is trading at US$103.69 after a 90 day share price return of 14.59%, even though the 1 year total shareholder return is down 21.93%. This points to momentum rebuilding in the short term after a tougher stretch for longer term holders. See how Abbott Laboratories compares with…Read More